–463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis

2007 ◽  
Vol 67 (4) ◽  
pp. 485-488 ◽  
Author(s):  
C Salvarani ◽  
B Casali ◽  
E Farnetti ◽  
N Pipitone ◽  
D Nicoli ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Polymyalgia Rheumatica ◽  
Visual Loss ◽  
Geographic Area ◽  
Population Based ◽  
Promoter Polymorphism ◽  
Reggio Emilia ◽  
Cerebrovascular Accidents

Objective:To investigate potential associations between–463 G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical features of giant cell arteritis (GCA).Methods:A total of 156 patients with biopsy-proven GCA who were residents of Reggio Emilia, Italy, and 235 population-based controls from the same geographic area were genotyped for–463 G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of polymyalgia rheumatica and severe ischaemic complications (visual loss and/or cerebrovascular accidents).Results:The distribution of the MPO-G/A genotype differed significantly between patients with GCA and the controls (pcorr = 0.003). Allele G was significantly more frequent in patients with GCA than in the controls (pcorr = 0.0002, OR 2.0, 95% CI 1.4 to 2.9). Homozygosity for the G allele was significantly more frequent in patients with GCA than in controls (pcorr = 0.0002, OR 2.2, 95% CI 1.4 to 3.4). No significant associations were found when patients with GCA with and without polymyalgia rheumatica or with and without severe ischaemic complications were compared.Conclusions:Our findings show that the–463 G/A promoter polymorphism of the MPO gene is associated with GCA susceptibility and support a role for MPO in the pathophysiology of GCA.

scholarly journals Clinical presentation and treatment response in patients with polymyalgia rheumatica and giant cell arteritis during a 40-week follow-up

2021 ◽  
Author(s):  
Amir Emamifar ◽  
Søren Hess ◽  
Torkell Ellingsen ◽  
Oke Gerke ◽  
Ziba Ahangarani Farahani ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Treatment Response ◽  
Giant Cell ◽  
Clinical Features ◽  
Polymyalgia Rheumatica ◽  
Fdg Pet ◽  
Temporal Artery Biopsy ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Objectives To study the clinical features of polymyalgia rheumatica and/or giant cell arteritis (PMR/GCA) and clinical predictors of treatment response during a 40-week follow-up period. Method Clinical data on 77 patients with newly diagnosed PMR/GCA who were treated by oral glucocorticoids were gathered at baseline and during 40-week follow-up period. A unilateral temporal artery biopsy (TAB) and 18 F-FDG PET/CT were undertaken at diagnosis. In total, each patient was seen at 5 occasions i.e. baseline, weeks 4, 16, 28, and 40. Treatment response was assessed considering clinical evaluations and results of inflammatory markers. Results Of 77 patients (49(63.6%) female, mean age : 71.8 ± 8.0), 64(83.1%) patients had pure PMR, 10(13.0%) concomitant PMR and GCA, and 3(3.9%) pure GCA. The patients reported clinical symptoms except scalp pain and duration of morning stiffness improved significantly at week 4 and remained lower at week 40 compared with the relative frequencies at baseline. Besides, all components of physical examination showed significant improvement and remained lower at week 40 compared with the baseline. 68.7%, 62.9%, 44.1% and 33.3% of the patients had a complete response at weeks 4, 16, 28, and 40, respectively. Several clinical features including female gender, younger age, fewer relapse, and lower level of baseline ESR were significantly associated with a better treatment response. Treatment response during follow-up period was independent of TAB results and FDG uptakes on 18 F-FDG PET/CT at diagnosis. Conclusion Obtaining valid disease specific outcome measures for evaluating treatment efficacy in PMR and GCA, that can be applied universally is clearly an unmet clinical need. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02985424

Polymyalgica rheumatica and giant cell arteritis

2008 ◽  
Vol 18 (2) ◽  
pp. 91-101 ◽  
Author(s):  
H A Bird ◽  
Helen Mac Iver
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Visual Loss ◽  
Temporal Arteritis ◽  
Morning Stiffness ◽  
Temporal Artery ◽  
Shoulder Girdle ◽  
Pelvic Girdle ◽  
Disease Spectrum

Polymyalgia rheumatica and giant cell arteritis are closely related conditions, considered by many to represent opposite poles of a single disease spectrum. They can occur together or separately.Polymyalgia rheumatica is characterized by pain and morning stiffness in the shoulder girdle and sometimes the pelvic girdle. The symptoms are felt to be related to synovitis of proximal joints and extra-articular synovial structures. Giant cell arteritis displays a frank vasculitis affecting the regions supplied by the temporal artery to give visual loss and scalp tenderness but is increasingly recognized to also affect the aorta and its extra-cranial branches. For this reason the term ‘giant cell arteritis’, which is descriptive of the pathology, is used instead of the alternative term ‘temporal arteritis’, which gives a misleading impression of localization but which was the term used in previous reviews for this journal, the most recent in 2003.

scholarly journals Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

BMC Medicine ◽  
2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Zoe Paskins ◽  
Rebecca Whittle ◽  
Alyshah Abdul Sultan ◽  
Sara Muller ◽  
Milica Blagojevic-Bucknall ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Population Based ◽  
Population Based Study ◽  
Risk Of Fracture

Clinical features of polymyalgia rheumatica and giant cell arteritis

2012 ◽  
Vol 8 (9) ◽  
pp. 509-521 ◽  
Author(s):  
Carlo Salvarani ◽  
Nicolò Pipitone ◽  
Annibale Versari ◽  
Gene G. Hunder
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Polymyalgia Rheumatica

Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis

2005 ◽  
Vol 53 (2) ◽  
pp. 293-297 ◽  
Author(s):  
Carlo Salvarani ◽  
Luca Cimino ◽  
Pierluigi Macchioni ◽  
Dario Consonni ◽  
Fabrizio Cantini ◽  
...  
Keyword(s):  
Risk Factors ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss ◽  
Population Based ◽  
Italian Population

scholarly journals Statin Use in Giant Cell Arteritis: A Retrospective Study

2013 ◽  
Vol 40 (6) ◽  
pp. 910-915 ◽  
Author(s):  
Jean Schmidt ◽  
Tanaz A. Kermani ◽  
Francesco Muratore ◽  
Cynthia S. Crowson ◽  
Eric L. Matteson ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Medical Records ◽  
Index Date ◽  
Clinical Information ◽  
Population Based ◽  
Acute Phase Reactants ◽  
Statin Use

Objective.(1) To examine the association between statin use and giant cell arteritis (GCA); (2) to compare the clinical features and disease course of GCA among statin users and nonusers.Methods.For this retrospective study, we reviewed the medical records of all patients with biopsy-positive GCA diagnosed between 1998 and 2008. Using a case-control design, we compared the frequency of statin use in GCA patients to non-GCA population-based subjects who were randomly selected and individually matched by sex, age, and calendar year to the GCA cases. Statin use at diagnosis or index date and during followup was abstracted. In subjects with GCA, clinical information at diagnosis and followup was collected.Results.We included 594 patients, 297 with GCA (73% female), mean age at diagnosis 75 years. The rate of statin exposure at index date was 18.1% for GCA patients versus 33.3% for controls (p < 0.001). Patients using statins were less likely to develop GCA compared with patients not using statins (OR 0.31, 95% CI 0.15–0.6, p < 0.001), even after adjustment for cardiovascular risk factors. Among patients with GCA, the presenting clinical features and acute-phase reactants were similar in patients receiving statins compared to those not on statin therapy. These 2 groups were also similar with regard to relapse rate, prednisone tapering, and overall survival.Conclusion.Patients using statins may be less likely to develop GCA compared to patients who are not using statins. Statin use does not appear to modify the clinical presentation or the course of the disease.

scholarly journals Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment

1998 ◽  
Vol 41 (8) ◽  
pp. 1497-1504 ◽  
Author(s):  
Miguel A. González-Gay ◽  
Ricardo Blanco ◽  
Vicente Rodríguez-Valverde ◽  
Victor M. Martínez-Taboada ◽  
Miguel Delgado-Rodriguez ◽  
...  
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Visual Loss ◽  
Response To Treatment ◽  
Cerebrovascular Accidents

Clinical features in patients with permanent visual loss due to biopsy- proven giant cell arteritis

Rheumatology ◽  
1997 ◽  
Vol 36 (2) ◽  
pp. 251-254 ◽  
Author(s):  
C. Font ◽  
M. C. Cid ◽  
B. Coll-Vinent ◽  
A. Lopez-Soto ◽  
J. M. Grau
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Visual Loss

The management of polymyalgia rheumatica and giant cell arteritis

1993 ◽  
Vol 31 (17) ◽  
pp. 65-68
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Clinical Features ◽  
Polymyalgia Rheumatica ◽  
Temporal Arteritis ◽  
Systemic Corticosteroid ◽  
Vascular Complications ◽  
Pure Form ◽  
Patient Treatment ◽  
Precise Relationship

Polymyalgia rheumatica and giant cell (cranial/temporal) arteritis are common debilitating conditions affecting people nearly always over the age of 55. Although the two syndromes are closely linked their precise relationship is not fully understood. Polymyalgia rheumatica or giant cell arteritis can occur in a ‘pure’ form or clinical features of each may be present in the same patient. Treatment with a systemic corticosteroid has long been considered mandatory in patients with giant cell arteritis in order to prevent serious vascular complications, particularly blindness1. Treatment with corticosteroid is also usual for patients with polymyalgia rheumatica. Many patients remain on steroids for years. What is the basis for current approaches to management? How should steroids be given and eventually stopped?

Sign in / Sign up

Export Citation Format

Share Document